日报更新时间：
周报更新时间：04-11 03:39
今开价：29.57
最高价：30.39
成交量：765087.0
昨收价：28.53
最低价：28.84
最新价：28.96
中文名称：Dicerna制药
英文名称：Dicerna Pharmaceuticals
行业：医疗
简介：Dicerna Pharmaceuticals, Inc.于2006年10月在特拉华州成立
电话：1-617-6218097
Dicerna Pharmaceuticals公司开发项目包括： DCR-PH1，可透过针对基因编码肝酶甘醇酸盐氧化酶，以治疗原发性高草酸盐尿症I型(PH1)，以及其他涉及基因表现之罕见遗传性肝疾病； DCR-MYC，用于治疗各种癌症患者实体肿瘤、多发性骨髓瘤及淋巴瘤，产品处Phase I临床研究阶段，以及治疗末期肝细胞癌之Phase Ib/II临床试验； 开发KRAS致癌基因，该基因为各种癌症，包括：非小细胞肺癌、直肠癌与胰脏癌之突变基因，也是第二癌症相关基因的治疗标靶。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2016-11-15 | Langer (Dennis H) | Director | Sell | 23766 | 3.52 |
| 2016-11-14 | Fambrough (Douglas M III) | Chief Executive Officer | Buy | 16500 | 3.63 |
| 2016-11-13 | Fambrough (Douglas M III) | Chief Executive Officer | Buy | 16600 | 3.78 |
| 2016-05-11 | Weissman (James B) | Officer | Buy | 4170 | 3.29 |
| 2016-05-11 | Weissman (James B) | Officer | Buy | 300 | 3.24 |
| 2016-05-11 | Weissman (James B) | Officer | Buy | 530 | 3.29 |
| 2016-02-02 | Langer (Dennis H) | Director | Buy | 34722 | 3.42 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Emerald Mutual Fund Advisers Trust | 891488 | 1.30% | -11951 | -1.32% | 2019-03-31 |
| RA Capital Management, LLC | 2456669 | 3.60% | -- | -- | 2019-03-31 |
| BlackRock Fund Advisors | 2469053 | 3.61% | 15650 | 0.64% | 2019-07-31 |
| Adage Capital Partners Gp LLC | 3050000 | 4.46% | -- | -- | 2019-03-31 |
| EcoR1 Capital, LLC | 3316407 | 4.85% | -- | -- | 2019-03-31 |
| BlackRock Inc | 4263619 | 6.24% | -67609 | -1.56% | 2019-03-31 |
| Bridger Management LLC | 4773718 | 6.99% | -- | -- | 2019-03-31 |
| RTW INVESTMENTS, LLC | 6223036 | 9.11% | 315948 | 5.35% | 2019-03-31 |
| Bain Capital Life Sciences Investors, LLC | 8930237 | 13.07% | -- | -- | 2019-03-31 |
| UBS Group AG | 2419121 | 3.54% | 1679033 | 226.87% | 2019-03-31 |
| Vanguard Group Inc | 2303289 | 3.37% | -37319 | -1.59% | 2019-03-31 |
| Citadel Advisors Llc | 2021610 | 2.96% | 20911 | 1.05% | 2019-03-31 |
| Artal Group S A | 979275 | 1.43% | 454275 | 86.53% | 2019-03-31 |
| Emerald Advisers, LLC | 996360 | 1.46% | -13970 | -1.38% | 2019-03-31 |
| Northern Trust Investments Inc | 1060598 | 1.55% | 31238 | 3.03% | 2019-07-31 |
| Goldman Sachs Group Inc | 1113748 | 1.63% | -118514 | -9.62% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1274739 | 1.87% | 45312 | 3.69% | 2019-07-31 |
| Point72 Asset Management, L.P. | 1350000 | 1.98% | 1350000 | -- | 2019-03-31 |
| Bvf Inc | 1400956 | 2.05% | 185229 | 15.24% | 2019-03-31 |
| State Street Corporation | 1881583 | 2.75% | -163307 | -7.99% | 2019-03-31 |
| BlackRock Asset Management Canada Ltd | 1257988 | 1.84% | -31 | -- | 2019-05-31 |
| Ghost Tree Capital, LLC | 1250000 | 1.83% | 150000 | 13.64% | 2018-12-31 |
| Geode Capital Management, LLC | 1109914 | 1.62% | 663969 | 148.89% | 2018-12-31 |
| Cormorant Asset Management, LLC | 3481471 | 5.10% | -75198 | -2.11% | 2018-12-31 |
| Fidelity Management and Research Company | 1102948 | 1.62% | -8514 | -0.77% | 2018-12-31 |
| FMR Inc | 1102948 | 1.62% | -8514 | -0.77% | 2018-12-31 |
| SSGA Funds Management Inc | 1194957 | 1.75% | -6962 | -0.58% | 2019-02-28 |
| Fidelity SelectCo, LLC | 1119557 | 1.78% | -124565 | -10.01% | 2019-02-28 |
| Fidelity Management & Research Company | 854744 | 1.36% | 19527 | 2.34% | 2018-11-30 |
| Goldman, Sachs & Co. | 1294594 | 2.06% | 765512 | 144.69% | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 834482 | 1.33% | 607030 | 266.88% | 2018-06-30 |
| Camber Capital Management LLC | 1000000 | 1.59% | -- | -- | 2018-03-31 |
| BCIP Life Sciences Associates, LP | 852338 | 1.65% | 65238 | 8.29% | 2017-12-18 |
| Emerald Advisers Inc | 603508 | 1.14% | 574804 | 2002.52% | 2018-06-30 |
| UBS Securities LLC | 606999 | 1.15% | 5177 | 0.86% | 2018-06-30 |
| State Street Corp | 739452 | 1.40% | 716869 | 3174.37% | 2018-06-30 |
| Domain Partners VIII, LP | 3469029 | 6.72% | 1716322 | 97.92% | 2017-12-18 |
| Bain Capital Life Sciences Fund, L.P | 8077899 | 15.64% | 618274 | 8.29% | 2017-12-18 |
| Palo Alto Investors, LLC | 500913 | 0.95% | -- | -- | 2018-06-30 |
| First Manhattan Company | 428100 | 0.83% | -- | -- | 2018-03-31 |
| Millennium Management LLC | 407530 | 0.79% | 340623 | 509.10% | 2018-03-31 |
| Emory University | 246411 | 0.48% | 246411 | -- | 2018-03-31 |
| Renaissance Technologies Corp | 289400 | 0.56% | -270900 | -48.35% | 2018-03-31 |
| Omega Fund Management LLC | 223457 | 0.43% | -- | -- | 2017-12-31 |
| Deutsche Bank AG | 168400 | 0.33% | 116719 | 225.85% | 2017-12-31 |
| Eventide Asset Management, LLC | 377000 | 1.81% | -- | -- | 2017-09-30 |
| 683 Capital Management LLC | 760233 | 3.65% | -39767 | -4.97% | 2017-09-30 |
| Bridgeway Capital Management, Inc | 168300 | 0.81% | 75000 | 80.39% | 2017-09-30 |
| Abingworth LLP | 794898 | 3.83% | -177836 | -18.28% | 2016-11-18 |
| Connor Clark & Lunn Inv Mgmt Ltd | 68975 | -- | -10300 | -12.99% | 2017-09-30 |
| Sunrise Partners LLC | 160000 | -- | -- | -- | 2017-06-30 |
| Sabby Management LLC | 190000 | -- | -10000 | -5.00% | 2017-06-30 |
| TIVERTON ASSET MANAGEMENT LLC | 128926 | 0.62% | -319032 | -71.22% | 2016-09-30 |
| Dafna Capital Management LLC | 119300 | 0.57% | -- | -- | 2016-09-30 |
| Oxford Asset Management, LLC | 59006 | 0.28% | -227407 | -79.40% | 2016-09-30 |
| Jacobs Levy Equity Management, Inc. | 55719 | 0.27% | -38700 | -40.99% | 2016-09-30 |
| D. E. Shaw & Co LP | 52340 | 0.25% | -22451 | -30.02% | 2016-09-30 |
| Abingworth Management Limited | 1182196 | 3.00% | 28561855 | 0.10% | 1999-11-30 |
| Skyline Ventures Partners V, L.P. | 1719671 | 3.00% | 41547251 | 0.10% | 1999-11-30 |
| Brian K. Halak | 1765711 | 3.00% | 42659578 | 0.10% | 1999-11-30 |
| Wellington Group Holdings LLP | 1819961 | 3.00% | 43970258 | 0.10% | 1999-11-30 |
| Peter Kolchinsky, Ph.D. | 2428571 | 3.00% | 58674275 | 0.10% | 1999-11-30 |
| Fidelity Management& Research Company | 2665993 | 3.00% | 64410391 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Northern Trust Russell 2000 Index DC NL | 156760 | 0.23% | 2438 | 1.58% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 1263059 | 1.85% | 45380 | 3.73% | 2019-06-30 |
| iShares Russell 2000 ETF | 1129578 | 1.65% | 2211 | 0.20% | 2019-07-30 |
| SPDR | 731776 | 1.07% | 14326 | 2.00% | 2019-07-31 |
| Vanguard Extended Market Index Fund | 727584 | 1.06% | 1160 | 0.16% | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 674464 | 0.99% | 6774 | 1.01% | 2019-07-30 |
| Emerald Growth Fund | 512950 | 0.75% | -40000 | -7.23% | 2019-05-31 |
| Candriam Eqs L Biotechnology | 477500 | 0.70% | 30000 | 6.70% | 2019-06-30 |
| iShares Russell 2000 Growth ETF | 476736 | 0.70% | 6665 | 1.42% | 2019-07-30 |
| State Street Russell Small/Mid Cap | 237990 | 0.35% | -- | -- | 2019-06-30 |
| NT R2000 Growth Index Fund - Non-Lending | 226193 | 0.33% | -5027 | -2.17% | 2019-06-30 |
| State Street Russell Small Cap | 223586 | 0.33% | -- | -- | 2019-06-30 |
| Fidelity | 218889 | 0.32% | 27347 | 14.28% | 2019-04-30 |
| NT R2000 Index Fund - NL | 206489 | 0.30% | 3904 | 1.93% | 2019-06-30 |
| Federated MDT Small Cap Growth Fund | 203169 | 0.30% | -- | -- | 2019-03-31 |
| MEDICAL BioHealth | 188673 | 0.28% | -- | -- | 2019-04-30 |
| Principal SmallCap Growth Fund I | 174031 | 0.25% | 1149 | 0.66% | 2019-06-30 |
| NT R2000 Growth Index Fund - Lending | 162680 | 0.24% | 1635 | 1.02% | 2019-06-30 |
| AST Small-Cap Growth Portfolio | 154902 | 0.23% | -- | -- | 2019-05-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 1106247 | 1.62% | -1854 | -0.17% | 2019-05-30 |
| Schwab US Small-Cap ETF | 150676 | 0.22% | -- | -- | 2019-04-30 |
| Invesco DWA SmallCap Momentum ETF | 148368 | 0.22% | -- | -- | 2019-03-31 |
| Federated MDT Small Cap Core Fund | 128078 | 0.19% | 37677 | 41.68% | 2018-12-31 |
| iShares Micro-Cap ETF | 131865 | 0.19% | -- | -- | 2019-02-28 |
| The Vanguard - Russell 2000 Grwth Idx CF | 95205 | 0.15% | -- | -- | 2019-01-31 |
| Schwab Small Cap Index Fund | 107197 | 0.17% | -- | -- | 2019-01-31 |
| Invesco DWA Healthcare Momentum ETF | 190865 | 0.30% | -- | -- | 2018-12-31 |
| Arctic Aurora LifeScience | 90000 | 0.14% | -- | -- | 2018-11-30 |
| Fidelity Advisor | 124565 | 0.20% | -77741 | -38.43% | 2018-07-31 |
| Eventide Healthcare & Life Sciences Fund | 377000 | 0.61% | -- | -- | 2017-09-30 |
| TIAA-CREF Small-Cap Blend Idx Inst | 54185 | 0.10% | -- | -- | 2018-07-31 |
| Bridgeway Ultra-Small Company Market | 60000 | 0.11% | -15000 | -20.00% | 2018-06-30 |
| BlackRock Russell 2500 | 60763 | 0.11% | 60763 | -- | 2018-06-30 |
| BlackRock Russell 2000 | 62644 | 0.12% | 62644 | -- | 2018-06-30 |
| CREF Stock R1 | 65084 | 0.12% | -3474 | -5.07% | 2018-07-31 |
| AXA 2000 Managed Volatility K | 67133 | 0.13% | -- | -- | 2018-07-31 |
| The Vanguard Russell 2000 Growth Index | 80223 | 0.15% | 1627 | 2.07% | 2018-07-31 |
| Schwab Small Cap Index | 82700 | 0.16% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 104825 | 0.20% | -- | -- | 2018-07-31 |
| Principal SmallCap Growth I Instl | 108570 | 0.21% | 3525 | 3.36% | 2018-07-31 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 109775 | 0.21% | -84 | -0.08% | 2018-07-31 |
| AST Small-Cap Growth | 132632 | 0.25% | -- | -- | 2018-07-31 |
| iShares Micro-Cap | 119064 | 0.19% | -- | -- | 2018-09-12 |
| Emerald Growth A | 289253 | 0.55% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 320401 | 0.61% | 3005 | 0.95% | 2018-07-31 |
| iShares Russell 2000 Growth | 430320 | 0.68% | -415 | -0.10% | 2018-09-12 |
| Vanguard Total Stock Mkt Idx | 826354 | 1.56% | -- | -- | 2018-07-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 51798 | 0.10% | -- | -- | 2018-06-30 |
| Vanguard Russell 2000 ETF | 49386 | 0.09% | 49386 | -- | 2018-06-30 |
| Northern Small Cap Index | 26100 | 0.05% | 26100 | -- | 2018-06-30 |
| Vanguard Balanced Index Inv | 29520 | 0.06% | -- | -- | 2018-05-31 |
| BlackRock Extended Equity Market K | 36625 | 0.07% | 22553 | 160.27% | 2018-06-30 |
| iShares Russell 3000 | 14713 | 0.03% | 13 | 0.09% | 2018-07-03 |
| Emerald Insights A | 10964 | 0.02% | -- | -- | 2018-05-31 |
| BNY Mellon EB DL Mkt Completion | 16034 | 0.03% | 10121 | 171.17% | 2018-03-31 |
| VALIC Company I Small Cap | 8300 | 0.02% | -- | -- | 2018-03-31 |
| iShares Core S&P Total US Stock Mkt | 5269 | 0.01% | 6 | 0.11% | 2018-05-24 |
| The Vanguard Total Stock Market Index | 6191 | 0.01% | -- | -- | 2018-04-30 |
| DFA Tax-Managed US Small Cap | 5800 | 0.01% | -- | -- | 2018-03-31 |
| Wilshire Micro-Cap ETF | 8362 | 0.02% | -- | -- | 2018-03-08 |
| Eventide Healthcare & Life Sciences A | 377000 | 1.81% | -- | -- | 2017-09-30 |
| BNY Mellon Market Completion Fund UC1 | 14491 | 0.07% | 13961 | 2634.15% | 2017-09-30 |
| TFS Market Neutral | 10368 | 0.05% | 10368 | -- | 2017-07-31 |
| Vanguard Health Care ETF | 24986 | 0.12% | -84 | -0.34% | 2016-12-31 |
| Vericimetry U.S. Small Cap Value | 11800 | 0.06% | 11800 | -- | 2016-09-30 |
| DFA US Micro Cap I | 7960 | 0.04% | -- | -- | 2016-12-31 |
| Fidelity® Select Biotechnology Portfolio | 659421 | 3.20% | -- | -- | 2015-10-31 |
| Hartford Healthcare Fund | 527073 | 2.60% | -- | -- | 2015-10-31 |
| Franklin Biotechnology Discovery | 370900 | 1.80% | -- | -- | 2015-07-31 |
| Fidelity® OTC Portfolio | 318629 | 1.60% | -- | -- | 2015-10-31 |
| Fidelity® Series Growth Company Fund | 293128 | 1.40% | -- | -- | 2015-10-31 |
| iShares Russell 2000 (AU) | 252495 | 1.60% | -156 | -0.10% | 2015-11-27 |
| Fidelity® Blue Chip Growth Fund | 160160 | 0.80% | -- | -- | 2015-10-31 |
| Hartford Healthcare HLS Fund | 137927 | 0.70% | -4930 | -3.50% | 2015-10-31 |
| Highland Long/Short Healthcare Fund | 129247 | 0.60% | 129247 | -- | 2015-06-30 |
| Fidelity Advisor® Biotechnology Fund | 125106 | 0.60% | -- | -- | 2015-10-31 |
| Fidelity® Growth Company Fund | 1086150 | 5.30% | -- | -- | 2015-10-31 |
| Ralf H. Rosskamp | Ralf H. Rosskamp occupies the position of Chief Medical Officer for Dicerna Pharmaceuticals, Inc. He previously was Chief Medical Officer for Summit Therapeutics Plc, Executive Vice President-Research & Development at KOS Pharmaceuticals, Inc., Executive Vice President-Research & Development at Ikaria, Inc., Global Clinical Director at Hoechst AG, Vice President-Global Clinical Development at NPS Pharmaceuticals, Inc., VP-Global Therapeutic Research & Development at Aventis Pharmaceuticals, Inc., Vice President of Global Therapeutics, Inc., Principal at Hoechst Pharmaceuticals Ltd. and Associate Professor at the University of Bonn. Dr. Rosskamp received a doctorate from the University of Bonn. |
|---|---|
| Dennis H. Langer | Dennis H. Langer founded Ception Therapeutics, Inc. Currently, Dr. Langer is Chairman of Light Sciences Oncology, Inc. He is also Professor at Georgetown University School of Medicine and on the board of 6 other companies. In his past career Dr. Langer held the position of President & Chief Executive Officer of Neose Technologies, Inc., Associate Clinical Investigator at Eli Lilly & Co., Managing Partner at Phoenix IP Ventures LLC, Associate Director-Clinical Research at Abbott Laboratories, Senior Director-Marketing at Searle & Co., Inc., Chief Executive Officer & Director at AdvanDx, Inc., Senior Vice President-Research & Development at GlaxoSmithKline LLC, President-North Americas Region at Dr. Reddy's Laboratories, Inc., Chief Resident at Yale School of Medicine and Director at Ception Therapeutics, Inc. Dr. Langer received a graduate degree from Harvard Law School, a doctorate from Georgetown University School of Medicine and an undergraduate degree from Columbia University. |
| Marc D. Kozin | Mr. Marc D. Kozin is a Lead Independent Director at UFP Technologies, Inc. He is on the Board of Directors at Dicerna Pharmaceuticals, Inc., UFP Technologies, Inc., GreenLight Fund, Inc. and Helomics Corp. Mr. Kozin was previously employed as an Independent Director by Frequency Therapeutics, Inc., an Independent Director by Flex Pharma, Inc., an Independent Director by OvaScience, Inc., an Independent Director by Dyax Corp., an Independent Director by Endocyte, Inc., and a President by LEK Consulting Pty Ltd. He also served on the board at Medical Simulation Corp., DukeEngage, Brandwise, Inc., CrunchTime! Information Systems, Inc., Lynx Therapeutics, Inc., Assurance Medical, Inc. and AdvizeX Technologies LLC. He received his undergraduate degree from Duke University and an MBA from The Wharton School of the University of Pennsylvania. |
| J. Kevin Buchi | Presently, J. Kevin Buchi occupies the position of Chairman at Dicerna Pharmaceuticals, Inc. Mr. Buchi is also on the board of Impax Laboratories LLC (former President, Chief Executive Officer & Director), ChemGenex Pharmaceuticals Pty Ltd., Benitec Biopharma Ltd. and Amneal Pharmaceuticals, Inc. J. Kevin Buchi previously occupied the position of President, Chief Executive Officer & Director at TetraLogic Pharmaceuticals Corp. and Vice President-Global Branded Products at Teva Pharmaceutical Industries Ltd. and Chief Executive Officer & Director at Cephalon, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.). J. Kevin Buchi received an undergraduate degree from Cornell University and a graduate degree from Kellogg School of Management. |
| Dennis H. Langer | Dennis H. Langer founded Ception Therapeutics, Inc. Currently, Dr. Langer is Chairman of Light Sciences Oncology, Inc. He is also Professor at Georgetown University School of Medicine and on the board of 6 other companies. In his past career Dr. Langer held the position of President & Chief Executive Officer of Neose Technologies, Inc., Associate Clinical Investigator at Eli Lilly & Co., Managing Partner at Phoenix IP Ventures LLC, Associate Director-Clinical Research at Abbott Laboratories, Senior Director-Marketing at Searle & Co., Inc., Chief Executive Officer & Director at AdvanDx, Inc., Senior Vice President-Research & Development at GlaxoSmithKline LLC, President-North Americas Region at Dr. Reddy's Laboratories, Inc., Chief Resident at Yale School of Medicine and Director at Ception Therapeutics, Inc. Dr. Langer received a graduate degree from Harvard Law School, a doctorate from Georgetown University School of Medicine and an undergraduate degree from Columbia University. |
| Bruce A. Peacock | Mr. Bruce A. Peacock, CPA, is an Executive Chairman at CARMA Therapeutics, Inc., an Independent Director at Dicerna Pharmaceuticals, Inc., an Independent Director at Ocular Therapeutix, Inc., an Independent Non-Executive Director at Windtree Therapeutics, Inc. and a Venture Partner at SV Health Investors LLC. He is on the Board of Directors at Invisible Sentinel, Inc., Dicerna Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Life Sciences Pennsylvania, Windtree Therapeutics, Inc., Sapphire Therapeutics, Inc., Othera Pharmaceuticals, Inc. and PanOptica, Inc. Mr. Peacock was previously employed as an Independent Director by Applied GeEnetic Technologies Corp., an Independent Non-Executive Director by Ocean Power Technologies, Inc., a Treasurer, Chief Financial & Business Officer by Ophthotech Corp., a Co-Chairman by Alba Therapeutics Corp., a Chief Executive Officer & Director by The Little Clinic LLC, a President, Chief Executive Officer & Director by Adolor Corp., a President, Chief Executive Officer & Director by Orthovita, Inc., a Chief Financial Officer & Senior Vice President by Centocor, Inc., and a Chief Operating Officer & Director by Cephalon, Inc. He also served on the board at Ligand Pharmaceuticals, Inc., Pharmacopeia, Inc. /Old/, NeurogesX, Inc. and Ikano Therapeutics, Inc. He received his undergraduate degree from Villanova University. |
| Stephen J. Hoffman | Stephen J. Hoffman is a businessperson who founded Somatogen, Inc. and who has been the head of 6 different companies. Dr. Hoffman occupies the position of Chief Executive Officer & Director at Aerpio Pharmaceuticals, Inc., Chief Executive Officer & Director at Aerpio Therapeutics, Inc. (a subsidiary of Aerpio Pharmaceuticals, Inc.), Managing Director at Skyline Management LLC and Chairman at Anchiano Therapeutics Ltd. Stephen J. Hoffman is also on the board of Dicerna Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc. (former Chief Executive Officer & Independent Director), Palleon Pharma, Inc. and Palleon Pharmaceuticals, Inc. In his past career Dr. Hoffman was Chairman of Bicycle Therapeutics Plc, Vice President-Science & Technology at Baxter International, Inc. and Vice President-Science & Technology at Somatogen, Inc. (a subsidiary of Baxter International, Inc.), General Partner at TVM Capital GmbH and General Partner at TVM Capital Corp. (a subsidiary of TVM Capital GmbH) and Chairman of Allos Therapeutics, Inc. Stephen J. Hoffman received a doctorate from Northwestern University and a doctorate from The University of Colorado School of Medicine. |
| John B. Green | John B. Green holds the position of Chief Financial Officer for Dicerna Pharmaceuticals, Inc. Mr. Green is also Vice President-Finance & Controller at Unum Therapeutics, Inc. Mr. Green previously occupied the position of Vice President-Finance of On-Q-ity, Inc., Chief Financial Officer of Verastem, Inc., Vice President & Assistant Treasurer at TSI Corp and Chief Financial Officer & Treasurer at rEVO Biologics, Inc. Mr. Green received an MBA from Boston University and an undergraduate degree from College of the Holy Cross (Massachusetts). |
| Douglas M. Fambrough | Dr. Douglas M. Fambrough joined Oxford Bioscience Partners in 1999. His past investments include RNA interference pioneer Sirna Therapeutics, and the ultra-high-through put DNA sequencing equipment company Solexa. Prior to Oxford, he was a genomic scientist at the Whitehead/MIT Center for Genome Research. Dr. Fambrough graduated from Cornell University and obtained his PhD in genetics from the University of California, Berkeley. |
| Brian K. Halak | Dr. Brian K. Halak is Partner at Domain Associates LLC and a Member at One Palmer Square Associates VI LLC. He is on the Board of Directors at Dicerna Pharmaceuticals, Inc., Carticept Medical, Inc., Alimera Sciences, Inc., BioNano Genomics, Inc., Corridor Pharmaceuticals, Inc., Kona Medical, Inc., Medico Hong Kong Ltd., Oraya Therapeutics, Inc. and Smart Medical Systems Ltd. Dr. Halak was previously employed as a Consultant by Wilkerson Group, an Associate by Advanced Technology Ventures, an Advisor by Ben Franklin Technology Partners, Member-Advisory Board by Elm Street Ventures, and an Advisor by The Biotechnology Greenhouse Corp. of Southeastern PA. He also served on the board at Vanda Pharmaceuticals, Inc., Cortria Corp., Domain Elite Holdings Ltd., Eddingpharm (Cayman), Inc., Esprit Pharma, Inc., Fenway Pharmaceuticals, Inc., GI Dynamics, Inc., Immune Control, Inc., Oceana Therapeutics, Inc., Optherion, Inc., Oraya Therapeutics, Inc., Tobira Therapeutics, Inc. /Old/ and Zyga Technology, Inc. Dr. Halak received his undergraduate degree from the University of Pennsylvania and a doctorate degree from Thomas Jefferson University. |
| Anna Protopapas | Anna Protopapas holds the position of President, Chief Executive Officer & Director at Mersana Therapeutics, Inc. Ms. Protopapas is also on the board of Dicerna Pharmaceuticals, Inc. In her past career she occupied the position of Corporate Officer at Takeda Pharmaceutical Co., Ltd. President & Chief Executive Officer at Takeda Oncology Co. and Head-Global Business Development at Takeda Pharmaceuticals International, Inc. (both are subsidiaries of Takeda Pharmaceutical Co., Ltd.). Anna Protopapas received an undergraduate degree from Princeton University, a graduate degree from Massachusetts Institute of Technology and an MBA from Stanford Graduate School of Business. |
| Martin I. Freed | Martin I. Freed founded Civitas Therapeutics, Inc. Dr. Freed is on the board of Dicerna Pharmaceuticals, Inc., Sojournix, Inc. and Solid Biosciences, Inc. Dr. Freed previously held the position of Senior Vice President-Clinical Development at Acorda Therapeutics, Inc. and Chief Medical Officer for Civitas Therapeutics, Inc. (a subsidiary of Acorda Therapeutics, Inc.), Chief Medical Officer of Taligen Therapeutics, Inc., Chief Medical Officer at Adnexus, Chief Medical Officer at Vitae Pharmaceuticals, Inc., Chief Medical Officer of Avila Therapeutics, Inc., VP-Clinical Development & Medical Affairs at GlaxoSmithKline LLC and VP-Clinical Development & Medical Affairs at Smithkline Beecham Pharmaceuticals (Canada). He received an undergraduate degree from the University of Delaware and a doctorate from Pennsylvania State University College of Medicine. |
| Peter Kolchinsky | Dr. Peter Kolchinsky is an Independent Director at Synthorx, Inc., at Wave Life Sciences Ltd., and at Dicerna Pharmaceuticals, Inc. and a Portfolio Manager & Managing Director at RA Capital Management LLC. He is on the Board of Directors at Synthorx, Inc., Sojournix, Inc., Wave Life Sciences Ltd., Dicerna Pharmaceuticals, Inc., Adeo Health Science, Inc., Cellscape Corp., Enlight Biosciences LLC, Ivantis, Inc., Lantos Technologies, Inc., Medeor Therapeutics, Inc., Periphagen Holdings, Inc., PiloFocus, Inc. and The American Fertility Association. He is also a founder of the firm RA capital. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a Board Member for various public and privately held companies. Dr. Kolchinsky was previously employed as an Independent Director by G1 Therapeutics, Inc., a Director-Science & Technology by National Academies of Sciences & Engineering, and a Member-National Academies Board by Global Science & Technology, Inc. He also served on the board at Calimmune, Inc. and ZipLine Medical, Inc. Dr. Kolchinsky holds a BS from Cornell University and a PhD in Virology from Harvard University. |
| Adam M. Koppel | Presently, Adam M. Koppel holds the position of Managing Director at Bain Capital Life Sciences LP. Dr. Koppel is also on the board of ViaCyte, Inc., Dicerna Pharmaceuticals, Inc., Aptinyx, Inc. and Solid Biosciences, Inc. Dr. Koppel previously held the position of Principal at Altus Pharmaceuticals, Inc., Associate Principal at McKinsey & Co., Inc., Executive VP-Strategy & Business Development at Biogen, Inc. and Managing Director at Bain Capital Public Equity LP. Dr. Koppel received an MBA from The Wharton School of the University of Pennsylvania, a doctorate from Perelman School of Medicine and an undergraduate degree and a graduate degree from Harvard College. |
| Regina M. DeTore Paglia | Regina M. DeTore Paglia occupies the position of Senior Vice President-Human Resources at Dicerna Pharmaceuticals, Inc. In the past she occupied the position of Vice President-Human Resources for Mascoma Corp., Senior Vice President-Human Resources for PTTGC Innovation America Corp., Manager-Human Resources at FMR LLC, Senior Vice President-Human Resources of Paratek Pharmaceuticals, Inc., Vice President-Human Resources of Sunovion Pharmaceuticals, Inc. and Director-Human Resources at Tufts Associated Health Plans, Inc. Ms. DeTore Paglia received a graduate degree from Framingham State College and an undergraduate degree from Sawyer Business School. |
| Peter Kolchinsky | Dr. Peter Kolchinsky is an Independent Director at Synthorx, Inc., at Wave Life Sciences Ltd., and at Dicerna Pharmaceuticals, Inc. and a Portfolio Manager & Managing Director at RA Capital Management LLC. He is on the Board of Directors at Synthorx, Inc., Sojournix, Inc., Wave Life Sciences Ltd., Dicerna Pharmaceuticals, Inc., Adeo Health Science, Inc., Cellscape Corp., Enlight Biosciences LLC, Ivantis, Inc., Lantos Technologies, Inc., Medeor Therapeutics, Inc., Periphagen Holdings, Inc., PiloFocus, Inc. and The American Fertility Association. He is also a founder of the firm RA capital. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a Board Member for various public and privately held companies. Dr. Kolchinsky was previously employed as an Independent Director by G1 Therapeutics, Inc., a Director-Science & Technology by National Academies of Sciences & Engineering, and a Member-National Academies Board by Global Science & Technology, Inc. He also served on the board at Calimmune, Inc. and ZipLine Medical, Inc. Dr. Kolchinsky holds a BS from Cornell University and a PhD in Virology from Harvard University. |
| Bob D. Brown | Bob D. Brown founded Oasis Biosciences, Inc. Currently, Dr. Brown is Chief Scientific Officer & Senior Vice President at Dicerna Pharmaceuticals, Inc. In the past Dr. Brown held the position of Vice President-Research & Development for Oasis Biosciences, Inc. and Vice President-Research & Technology at Genta, Inc. Dr. Brown received a doctorate from the University of California, Berkeley and an undergraduate degree from the University of Washington. |
| James B. Weissman | James B. Weissman is Chief Business Officer for Dicerna Pharmaceuticals, Inc. In the past Mr. Weissman held the position of Director & Vice President at North Jersey Masters Track & Field Club, Vice President-Business Development at MannKind Corp., Senior Director-Marketing at Pfizer Japan, Inc. and Head-Business Development & Marketing at Pfizer Pharmaceuticals, Inc. Mr. Weissman received an undergraduate degree from Bates College. |
| Cynthia Smith | Cynthia Smith is on the board of Dicerna Pharmaceuticals, Inc., Akebia Therapeutics, Inc., French-American Foundation and Spero Therapeutics, Inc. She previously was VP-Market Access & Commercial Development at Affymax, Inc., Executive Director-Healthcare System at Merck & Co., Inc. and Chief Commercial Officer at ZS Pharma, Inc. Ms. Smith received an undergraduate degree from the University of North Carolina at Chapel Hill, an MBA from The Wharton School of the University of Pennsylvania and a graduate degree from Eagleton Institute of Politics. |
| David W. Miller | Founder of EcoScience Corp., David W. Miller is on the board of Ecopesticides International, Inc. and SVP-Operations & Alliance Management at Dicerna Pharmaceuticals, Inc. He previously held the position of Director-Business Development at Altus Pharmaceuticals, Inc., Head-Research at EcoScience Corp., Senior Director-Business Development at Synta Pharmaceuticals Corp. and Principal at Genetics Institute LLC. He received a doctorate from Harvard University and an undergraduate degree from the University of California, Davis. |
| David J. Caponera | David J. Caponera is Head-Patient Advocacy & Patient Services at Dicerna Pharmaceuticals, Inc. In the past he was VP-Patient Engagement & Access Support at Catalyst Pharmaceuticals, Inc. Mr. Caponera received an undergraduate degree from Cornell University and a graduate degree from Duke University. |
| Hardean E. Achneck | Hardean E. Achneck is Member of American Heart Association, Inc., Member of The International Society of Thrombosis & Hemostasis, Member of The European Society of Cardiology, Member of American Society of Gene & Cell Therapy and Vice President & Head-Medical Development at Dicerna Pharmaceuticals, Inc. In his past career he was Chief Medical Officer of Hemostemix, Inc. Dr. Achneck received an undergraduate degree from Yale University and a doctorate from Yale School of Medicine. |
| Steven A. Kates | Steven A. Kates is Vice President-Technology for Arch Therapeutics, Inc. and Vice President-Regulatory Affairs at Dicerna Pharmaceuticals, Inc. Dr. Kates is also on the board of American Chemical Society and American Peptide Society, Inc. and Member of Association of Biomolecular Research Facilities. Dr. Kates received an undergraduate degree from Bates College and a doctorate from Brandeis University. |
| Rob Ciappenelli | Rob Ciappenelli is Chief Commercial Officer of Dicerna Pharmaceuticals, Inc. Mr. Ciappenelli received an undergraduate degree from the University of Massachusetts and an MBA from Harvard Business School. |
| Bernd Hoppe | Bernd Hoppe is on the board of Oxalosis & Hyperoxaluria Foundation. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论